Tag: prostate cancer

1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1 (pelvic bed radiotherapy alone). ...

1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”) had the best overall survival and progression-free survival ...

1. Bone mineral density testing was associated with a significant decreased risk of developing major osteoporotic fractures among older men ...

1. Patients with hormone-sensitive prostate cancer receiving darolutamide, an androgen-receptor inhibitor, in addition to standard therapy demonstrated longer overall survival ...

1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to ...

1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to ...

1. In this retrospective cohort study, there was no significant difference in all-cause mortality between patients with prostate cancer and ...

1. For the detection of pelvic nodal metastases in men with intermediate-to high-risk prostate cancer, using the 68Ga-PSMA-11 PET scan, the ...

1. For the detection of pelvic nodal metastases in men with intermediate-to high-risk prostate cancer, using the 68Ga-PSMA-11 PET scan, ...

1. Magnetic resonance imaging with targeted and standard biopsy was non-inferior for the detection of clinically significant cancers compared to ...